Evidence map›Paper›PMID 41584329›Full record

ReviewActa pharmaceutica Sinica. B2026

Computational approaches to druggable site identification: Current status and future perspective.

Anqi Lin, Zhirou Zhang, Aimin Jiang, Kexin Li, Ying Shi, Hong Yang, Jian Zhang, Rongrong Liu, Yaxuan Wang, Antonino Glaviano and 4 more

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anqi LinDonghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang 222000, China.
Zhirou ZhangDonghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang 222000, China.
Aimin JiangDepartment of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai 200433, China.
Kexin LiDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Ying ShiDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Hong YangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Rongrong LiuDepartment of Oncology, the First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Yaxuan WangDepartment of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Antonino GlavianoDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo 90123, Italy.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhengang QiuDepartment of Oncology, the First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Peng LuoDonghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang 222000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rapid advancements in computer technology and bioinformatics, the prediction of protein-ligand-binding sites has become a central component of modern drug discovery and development. Traditional experimental methods are often constrained by long experimental cycles and high costs; therefore, the development of accurate and efficient computational methods is of paramount significance for conserving time and cost. This review comprehensively summarizes the methodological advancements and current applications in the field of screening for druggable protein target sites, systematically comparing the fundamental principles, advantages, and disadvantages of four main categories of methods: structure- and sequence-based methods, machine learning-based methods, binding site feature analysis methods, and druggability assessment methods. Subsequently, by integrating classic case studies, this paper elaborately discusses the technical support and theoretical guidance afforded by the screening of protein druggable target sites for drug discovery and drug repositioning. Finally, this paper thoroughly explores the current challenges inherent in the field of protein-ligand binding site prediction, with a particular focus on future technological trends, systematically elucidating the developmental prospects and potential applications of these predictive methods.

Indexed as

Allosteric siteCryptic siteDrug discoveryDruggability assessmentGPCRsLigand-binding siteMachine learningMolecular dynamics simulation

Identifiers

PMID41584329
PMCPMC12827903

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.